Developing a single new pharmaceutical drug costs billions of dollars and routinely takes up to a decade, bottlenecked by incredibly high failure rates. To cut through this timeline, SandboxAQ integrated its proprietary Large Quantitative Models for drug discovery directly into Anthropic’s Claude artificial intelligence model.
The integration launched in May 2026 to solve a specific industry problem. Biotech researchers can now interact with highly complex chemical simulations using natural language prompts rather than writing custom code or relying on dedicated software engineers.
Bypassing the machine learning degradation wall
Standard machine learning models often fall apart when researchers ask them to explore entirely new, untested chemical spaces. SandboxAQ tackles this by combining statistical machine learning with physics-grounded simulations. When traditional AI hits a dead end, the physics-based side steps in to maintain accuracy.
This hybrid approach already showed results in previous internal tests. During a project focusing on neurodegenerative diseases, the system expanded the searchable chemical space from 250,000 to 5.6 million molecules, triggering a 30-fold increase in hit rates, according to the initial TechCrunch report released on Monday.
How SandboxAQ’s accessibility play counters Isomorphic Labs
Most venture-backed competitors in the AI drug discovery sector are currently engaged in an arms race over raw baseline power. Companies like Isomorphic Labs and Chai Discovery dedicate enormous resources to building fundamentally stronger underlying models. SandboxAQ is taking a completely different bet.
By using Claude as the primary interface, SandboxAQ assumes that access and usability are the true obstacles holding back biotech advancements. Instead of just trying to build a smarter system, they are attempting to put their existing high-tier simulations into the hands of standard laboratory researchers who lack advanced computing degrees.